Grimley, M., Prasad, V. K., Kurtzberg, J., Chemaly, R. F., Brundage, T. M., Wilson, C., & Mommeja-Marin, H. (2014). Twice-Weekly Brincidofovir (CMX001) Shows Promising Antiviral Activity in Immunocompromised Transplant Recipients with Asymptomatic Adenovirus Viremia. In Biology of Blood and Marrow Transplantation (Vol. 20, pp. S93–S93). Elsevier BV. https://doi.org/10.1016/j.bbmt.2013.12.120

Grimley, Michael, Vinod K. Prasad, Joanne Kurtzberg, Roy F. Chemaly, Thomas M. Brundage, Chad Wilson, and Herve Mommeja-Marin. “Twice-Weekly Brincidofovir (CMX001) Shows Promising Antiviral Activity in Immunocompromised Transplant Recipients with Asymptomatic Adenovirus Viremia.” In Biology of Blood and Marrow Transplantation, 20:S93–S93. Elsevier BV, 2014. https://doi.org/10.1016/j.bbmt.2013.12.120.

Grimley M, Prasad VK, Kurtzberg J, Chemaly RF, Brundage TM, Wilson C, et al. Twice-Weekly Brincidofovir (CMX001) Shows Promising Antiviral Activity in Immunocompromised Transplant Recipients with Asymptomatic Adenovirus Viremia. In: Biology of Blood and Marrow Transplantation. Elsevier BV; 2014. p. S93–S93.

Grimley, Michael, et al. “Twice-Weekly Brincidofovir (CMX001) Shows Promising Antiviral Activity in Immunocompromised Transplant Recipients with Asymptomatic Adenovirus Viremia.” Biology of Blood and Marrow Transplantation, vol. 20, no. 2, Elsevier BV, 2014, pp. S93–S93. Crossref, doi:10.1016/j.bbmt.2013.12.120.

Grimley M, Prasad VK, Kurtzberg J, Chemaly RF, Brundage TM, Wilson C, Mommeja-Marin H. Twice-Weekly Brincidofovir (CMX001) Shows Promising Antiviral Activity in Immunocompromised Transplant Recipients with Asymptomatic Adenovirus Viremia. Biology of Blood and Marrow Transplantation. Elsevier BV; 2014. p. S93–S93.